Ensign Peak Advisors Inc bought a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company’s stock, valued at approximately $1,495,000. Ensign Peak Advisors Inc owned approximately 0.09% of Design Therapeutics at the end of the most recent quarter.
Shares of DSGN opened at $22.57 on Friday. Design Therapeutics, Inc. has a 1-year low of $18.55 and a 1-year high of $50.50. The company has a fifty day moving average of $25.17.
Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings results on Monday, May 10th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.25). As a group, equities analysts predict that Design Therapeutics, Inc. will post -0.85 EPS for the current year.
Design Therapeutics Profile
Design Therapeutics, Inc develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy.
Featured Article: How a Put Option Works
Want to see what other hedge funds are holding DSGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Design Therapeutics, Inc. (NASDAQ:DSGN).
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.